Should an adult with acute viral upper‑respiratory infection and pharyngitis be treated with zinc lozenges, and what dosing and safety considerations apply?

Zinc Lozenges for Acute Viral Upper Respiratory Infection with Pharyngitis

For adults with acute viral upper respiratory infection and pharyngitis, zinc lozenges (zinc acetate or zinc gluconate) at doses ≥75 mg/day should be considered if started within 24 hours of symptom onset, as they may reduce cold duration by approximately 2 days, though patients must be counseled about common side effects including bad taste and nausea.

Evidence-Based Recommendation

The most recent and highest-quality guideline evidence comes from the 2020 European Position Paper on Rhinosinusitis and Nasal Polyps 1, which provides clear guidance on zinc use for the common cold. This guideline explicitly states that zinc administered as zinc acetate or zinc gluconate lozenges at a dose of ≥75 mg/day, taken within 24 hours of onset of symptoms, significantly reduces the duration of common cold 1.

Key Implementation Points

Dosing specifications:

• Minimum effective dose: ≥75 mg elemental zinc per day 1
• Formulations: Zinc acetate or zinc gluconate lozenges
• Critical timing: Must initiate within 24 hours of symptom onset 1
• Duration: Continue throughout the entire cold 1

Expected clinical benefit:

• Reduction in cold duration of approximately 2-2.4 days 2, 3
• May reduce symptom severity, though evidence is mixed 2
• Approximately 19 fewer adults per 100 remain symptomatic at day 7 (NNT=5) 3

Safety Considerations and Side Effects

Common adverse effects that patients must understand:

• Bad taste reactions: Occurs in up to 80% of zinc recipients 4
• Nausea: Affects approximately 20% of patients 4
• Mouth/nasal irritation 3
• Overall non-serious adverse events occur in approximately 90% of zinc users versus 62% with placebo 4

The benefit-risk calculation: The 2020 guideline explicitly acknowledges this trade-off, stating: "When using zinc lozenges the likely benefit has to be balanced against side effects, notably a bad taste and nausea" 1. This requires shared decision-making with patients - they must decide whether a 2-day reduction in cold duration justifies the high likelihood of unpleasant taste and possible nausea.

Important Clinical Caveats

When NOT to Use Zinc

Zinc is NOT indicated for:

• Bacterial pharyngitis (Group A Streptococcus) - The IDSA pharyngitis guidelines 5 make no mention of zinc for streptococcal pharyngitis, which requires appropriate antibiotics
• Patients who present >24 hours after symptom onset (efficacy unclear)
• Intranasal zinc formulations (associated with anosmia risk, though not discussed in lozenges)

Diagnostic Clarity Required

Before recommending zinc, you must differentiate viral from bacterial pharyngitis:

Features suggesting VIRAL etiology (appropriate for zinc consideration):

• Cough, rhinorrhea, hoarseness, oral ulcers 5
• Gradual onset
• Symptoms peak within 3 days then gradually decline 6

Features suggesting BACTERIAL pharyngitis (requires testing/antibiotics, NOT zinc):

• Persistent fever, anterior cervical adenitis, tonsillopharyngeal exudates 7
• Modified Centor score ≥2 5
• Absence of viral features

Strength of Evidence and Limitations

The 2024 Cochrane review 2 provides the most comprehensive recent analysis (34 RCTs, 8526 participants) but found low-certainty evidence for treatment benefit, with wide variation in interventions and outcomes. The evidence shows zinc "may reduce the duration of ongoing colds" but with significant heterogeneity (I² = 97%) 2.

Critical evidence limitations:

• Most studies at unclear or high risk of bias 2
• Conflicting results across trials 8, 9, 10
• Incomplete reporting of adverse events
• No studies specific to SARS-CoV-2 3

Despite these limitations, the 2020 European guideline provides the most authoritative synthesis and makes a clear recommendation based on available evidence 1.

Practical Prescribing Algorithm

Step 1: Confirm viral etiology (presence of cough, rhinorrhea, hoarseness; absence of bacterial features)

Step 2: Verify timing (<24 hours from symptom onset)

Step 3: Counsel patient on:

• Expected benefit: ~2 days shorter cold duration
• High likelihood (80-90%) of bad taste
• 20% risk of nausea
• Need to continue throughout illness

Step 4: If patient accepts trade-off, prescribe:

• Zinc gluconate or zinc acetate lozenges
• ≥75 mg elemental zinc daily
• One lozenge every 2 hours while awake
• Continue until symptoms resolve

Step 5: Recommend adjunctive symptomatic therapy:

• Acetaminophen or NSAIDs for pain/fever 5
• Nasal saline 6
• Avoid aspirin in children 5

Alternative Considerations

The FDA drug labels 11 provided relate to intravenous zinc for nutritional supplementation, not oral lozenges for cold treatment, and are therefore not applicable to this clinical scenario.

For patients who decline zinc due to side effect concerns, symptomatic management alone is reasonable given the self-limited nature of viral URIs (typically resolve within 7-10 days) 6, 7.